<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Zervas, K.</style></author><author><style face="normal" font="default" size="100%">Pouli, A.</style></author><author><style face="normal" font="default" size="100%">Gregoraki, B.</style></author><author><style face="normal" font="default" size="100%">Anagnostopoulos, N.</style></author><author><style face="normal" font="default" size="100%">Dimopoulos, M.A.</style></author><author><style face="normal" font="default" size="100%">Bourantas, K.</style></author><author><style face="normal" font="default" size="100%">Tzilianos, M.</style></author><author><style face="normal" font="default" size="100%">Barbarousi, D.</style></author><author><style face="normal" font="default" size="100%">Venetis, E.</style></author><author><style face="normal" font="default" size="100%">Vyniou, N.</style></author><author><style face="normal" font="default" size="100%">Maniatis, A.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Comparison of vincristine, carmustine, melphalan, cyclophosphamide, prednisone (VBMCP) and interferon-α with melphalan and prednisone (MP) and interferon-α (IFN-α in patients with good-prognosis multiple myeloma: A prospective randomized study</style></title><secondary-title><style face="normal" font="default" size="100%">European Journal of Haematology</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Chemotherapy</style></keyword><keyword><style  face="normal" font="default" size="100%">Interferon-α</style></keyword><keyword><style  face="normal" font="default" size="100%">myeloma</style></keyword><keyword><style  face="normal" font="default" size="100%">Prognostic factors</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2001</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2001</style></date></pub-dates></dates><urls><web-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-0035140386&amp;doi=10.1034%2fj.1600-0609.2001.00285.x&amp;partnerID=40&amp;md5=95bd0369534c4f4184782d1853dfd9aa</style></url></web-urls></urls><volume><style face="normal" font="default" size="100%">66</style></volume><pages><style face="normal" font="default" size="100%">18 - 23</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">Objectives: The purpose of the study was to evaluate, in a selected group of myeloma patients with favorable prognosis, the effect, on response and survival, of polychymotherapy compared with melphalan-prednisone, plus interferon in both arms. Methods: Eighty-nine previously untreated patients with multiple myeloma and prognostic factors indicating a good prognosis were randomized to either oral melphalan plus prednisone (MP) in combination with recombinant interferon-α (rIFN-α) or combination chemotherapy with vincristine, carmustine, melphalan, cyclophosphamide, and prednisone (VBMCP) alternating with rIFN-α. The two treatment groups were comparable in terms of pretreatment characteristics. Results: The overall response rate was 67.4% (2.3% complete remission, 65.1% partial response) in the MP/IFN-α group and 69.1% (14.3% complete remission, 54.8% partial response) in the VBMCP/IFN-α group (p = 0.59). There were no differences also in response duration and overall survival between the two treatment groups. The median response duration was 39.1 months in the MP/IFN-α group and was not reached in the VBMCP/IFN-α group (p = 0.6). Overall survival was long in both treatment groups. The estimated 5-yr survival was 66% and 62% in the MP/IFN-α and VBMCP/IFN-α group, respectively (p = 0.8). Toxicity was modest and treatments were well tolerated. Neutropenia (WHO grade 3 or 4) was higher, but not statistically significant, in the VBMCP/IFN-α group. Conclusions: The results of the study show that in myeloma patients with good prognosis, combination chemotherapy alternating with interferon-α has no advantage over conventional MP plus interferon-α, in regard to response rate, response duration, and overall survival of patients. © Munksgaard 2001.</style></abstract><issue><style face="normal" font="default" size="100%">1</style></issue><notes><style face="normal" font="default" size="100%">Cited By :8Export Date: 21 February 2017</style></notes></record></records></xml>